Announcement of Commencement of Domestic Phase III Clinical Trial for Cytomegalovirus Endotheliitis
Jul 20, 2021
ROHTO Pharmaceutical Co., Ltd. (Head Office: Osaka, hereinafter referred to as "ROHTO Pharmaceutical") is pleased to announce the commencement of a domestic Phase III clinical trial targeting patients with Cytomegalovirus Endotheliitis for the antiviral agent "Development Code ROH-101 (generic name: Ganciclovir)" (hereinafter referred to as "the drug").
Cytomegalovirus Endotheliitis is a condition caused by inflammation of the corneal endothelial cells due to cytomegalovirus infection, resulting in reduced vision due to corneal edema and opacity. As there are currently no approved treatments for this condition both domestically and internationally, the development of a therapeutic agent is highly anticipated.
Ganciclovir is an antiviral drug that inhibits viral DNA polymerases.
In the field of ophthalmology, It is approved as a treatment for Simple Herpes Eye Infection in over 40 countries worldwide.
- Cytomegalovirus Endotheliitis
Endotheliitis is a condition that causes inflammation of the corneal endothelial cells. When corneal endothelial cells are extensively damaged, it can lead to bullous keratopathy, resulting in severe vision impairment and, in some cases, blindness. Although the existence of Cytomegalovirus Endotheliitis was first reported in Japan in 2006, there are currently no approved treatments for this condition both domestically and internationally.
Théa is a European independent pharmaceutical group company leading the field of ophthalmology.
As a family-owned company, Théa is a pioneer in preservative-free eye drops and offers a wide range of ophthalmic treatments.
Based in Clermont-Ferrand, France, Théa has approximately 30 subsidiaries and overseas locations across Europe, North America, South America, North Africa, and the Middle East.
With around 1,500 employees worldwide, its products are sold in various countries.
For more information, please visit https://www.laboratoires-thea.com/en
About M's Science Corporation
M's Science Corporation is a drug discovery biotechnology venture company specialized in research and development of medical pharmaceuticals, founded in November 2000.